What is your diagnosis when you see vulvar fissures?
A. Lichen sclerosus flare
|A. Wet preparation (saline and 10% KOH)||A. 10%|
|B. Vulvar candidiasis||B. Yeast culture, and if positive, identification of species||B. 25%|
|C. Vulvovaginal atrophy||C. Vulvar biopsy||C. 50%|
|D. A & B||D. 75%|
|Diagnosis||B. Vulvar candidiasis|
|Tests to consider||D. Wet preparation and yeast culture|
|Percent Affected||D. 75%|
Figure 1 demonstrates vulvar fissures, which are linear erosions (loss of epithelium) that can be seen in a number of vulvar diseases, including lichen sclerosus, Candida infections, herpes simplex virus infections, lichen simplex chronicus (itch-scratch), Crohn’s disease, or tearing from the genitourinary syndrome of menopause.1,2 Patients with vulvar fissures often describe them as stinging or burning pain that feels similar to a paper cut.1
In this patient’s case, we are drawn away from a lichen sclerosus flare as the diagnosis given the fact that she was previously well-controlled on topical corticosteroids. Long-term studies have demonstrated that topical corticosteroids are safe for lichen sclerosus and decrease the chance of developing cancer if used regularly.3,4 However, we know that these drugs can increase risk of infections, especially Candida.1,3 Thus whenever patients with lichen sclerosus do not respond or are no longer responding to therapy for lichen sclerosus, you should consider other causes of their worsening symptoms, such as infection or coexisting vulvar conditions.1
The first step in evaluation of this patient would be to obtain a sample for a wet preparation with saline and 10% KOH and consider a yeast culture (identify the species if positive).1,5 The advantage to performing direct microscopy is that you can obtain an immediate diagnosis. However, yeast is missed on 50% of wet mounts. So, if the wet prep is negative, or the patient has not responded to prior antifungal treatments, a yeast culture to identify the species and guide your treatment should be considered. Yeast cultures are most helpful in recurrent or resistant infections.
Up to 75% of all women will have at least one episode of vulvovaginal candidiasis with 10% to 20% of women being classified as having complicated infections.6 Complicated infections are defined as those that are recurrent, severe, or that occur in patients with diabetes or who are immunocompromised.4 Most commonly candidiasis is caused by Candidaalbicans but other species can also be identified, including C. glabrata and C. krusei, which can be resistant to first-line therapies.1,5,6 Risk factors for developing this fungal infection include recent antibiotic usage, incontinence, obesity, diabetes mellitus, and immunosuppression (including local topical steroid use).1,5
Most commonly, patients present with vulvar pruritus and may have thick white vaginal discharge.4,5 On examination you may also see vulvar fissures, excoriations, and erythema. The diagnosis is confirmed via vaginal pH measurement (from the lateral side wall of the vagina) and wet mount. Classic microscopic findings include pseudohyphae (Figure 2). As mentioned above, a yeast culture may be beneficial in cases of recurrent or resistant infections, defined as four or more infections per year, or infections that are unresponsive to treatment.6 We would recommend treating this patient for complicated vulvovaginal candidiasis given her topical corticosteroid use. Treatment can be topical or oral. Topical treatments to the vulva include miconazole nitrate 2% cream twice daily for up to 7 days or nystatin ointment 100,000 units/gram two to three times per day for up to 7 to 14 days.6 Intravaginal antifungal treatment (numerous azole medications are available) should be given along with the topical treatment to the vulva. Oral treatments include fluconazole, 150 mg for every 72 hours for three doses, before starting a maintenance antifungal regimen.6 For recurrent infections, weekly fluconazole can be used for up to 6 months.
For additional information, a yeast app is available in the app store (type in ISSVD). This app was developed by the International Society for the Study of Vulvovaginal Disease with an unrestricted educational grant from Prestige, Inc., manufacturers of Monistat. The company had no input into the app content, or development of treatment recommendations.
This is a chronic inflammatory condition of the skin that is likely autoimmune in nature. Patients typically present with vulvar pruritus, burning or pain with intercourse.4 They may also be asymptomatic. Lichen sclerosus is characterized by classical skin changes, which include whitening of the skin that can be scattered or diffuse with atrophy and a cigarette paper/cellophane appearance.1,5 Often the condition manifests in a figure of eight pattern around the vaginal opening and anus.1,5 There may also be thickened areas and fissuring. Vulvar biopsy confirms the diagnosis although the clinical appearance can be utilized as well.1
As mentioned previously, treatment is with topical corticosteroids. For lichen sclerosus, clobetasol 0.05% ointment is used up to twice daily for 1 month followed by daily for 2 months and then the patient is maintained on topical triamcinolone 0.1% ointment daily. An alternative regimen is to treat as above, for 3 months with clobetasol 0.05% ointment, then use clobetasol 0.05% ointment three times weekly long term.
A decrease in circulating estrogen that comes with menopause results in thinning of vaginal epithelium.1 This increases the likelihood of erosions and secondary infection.1 Patients often present with complaints of dryness, pruritus, and dyspareunia. Erosions or fissuring from friction may be seen.1 The diagnosis is made based on the clinical appearance of the vaginal mucosa and vulvar skin. On wet preparation, you would see parabasal cells (small, round, immature epithelial cells), elevated vaginal pH (greater than 4.5) and loss of lactobacilli.1 First-line treatment is the use of lubricants.7 Patients who do not respond to this therapy may benefit from a trial of local estrogen therapy, ospemifene, or prasterone.7
Hope K. Haefner, MD, is on the advisory board of Prestige, Inc.